Search Tag: prostate cancer
2024 23 Sep
Prostate cancer (PCa) remains one of the most common malignancies among men worldwide, and accurate staging is crucial for effective treatment planning. Recently, positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA) tracers has improved the detection of PCa metastases. One of the newer tracers,...Read more
2024 16 Sep
Prostate cancer is the second most common cancer among men worldwide, making early detection crucial for reducing morbidity and mortality rates. One of the key tools for identifying clinically significant prostate cancer (csPCa) is multiparametric magnetic resonance imaging (mpMRI). However, the process of detecting prostate cancer through mpMRI...Read more
2024 16 Sep
Active surveillance (AS) has become a widely recommended approach for managing patients with low or favourable intermediate-risk prostate cancer. This strategy aims to delay or avoid radical treatments and their associated side effects while maintaining effective cancer control. Magnetic resonance imaging (MRI), particularly multiparametric MRI...Read more
2024 22 Jul
Over the past decade, MRI-targeted biopsy has emerged as a superior method for detecting clinically significant prostate cancer (csPCa) compared to systematic biopsy. Randomized studies have consistently demonstrated its efficacy. However, MRI fails to detect up to one-third of csPCa cases. This shortfall is influenced by histopathologic features...Read more
2024 19 Jun
Prostate cancer (PCa) is highly prevalent globally among men, necessitating improved diagnostic accuracy, especially for clinically significant cases (csPCa) requiring aggressive treatment to reduce mortality. While prostate-specific antigen (PSA) is commonly used for screening, its reliance leads to over-diagnosis concerns due to lack of cancer...Read more
2024 19 Jun
Prostate cancer (PCa) treatment strategies are evolving, with increasing interest in focal therapy (FT) as a less invasive alternative to traditional prostatectomy and radiation therapy. FT aims to eradicate cancer while preserving quality of life, making accurate cancer contouring crucial for treatment success. However, conventional methods often...Read more
2024 29 May
While multiparametric magnetic resonance imaging (mpMRI) has become integral in prostate cancer (PCa) diagnosis, there's a debate regarding the inclusion of dynamic contrast-enhanced (DCE) sequences in future PI-RADS iterations due to questionable benefits. To address time constraints, biparametric (bp) protocols, omitting DCE sequences, have...Read more
2024 02 May
Active surveillance (AS) is endorsed by the European Association of Urology (EAU) for low to favourable intermediate-risk prostate cancer (PCa) patients. It aims to delay or avoid radical treatments while maintaining oncological outcomes. AS's safety is supported by trials like ProtecT and PIVOT, despite potential understaging and undergrading....Read more
2024 05 Apr
A groundbreaking study presented at the Society of Interventional Radiology Annual Scientific Meeting unveils the potential of a minimally invasive treatment for prostate cancer using MRI-guided transurethral ultrasound ablation (TULSA). This innovative approach offers an effective alternative to traditional treatments like surgery or radiation,...Read more
2024 05 Apr
A groundbreaking study presented at the Society of Interventional Radiology Annual Scientific Meeting unveils the potential of a minimally invasive treatment for prostate cancer using MRI-guided transurethral ultrasound ablation (TULSA). This innovative approach offers an effective alternative to traditional treatments like surgery or radiation,...Read more
2024 09 Dec
<marquee behavior="slide" direction="left" scrollamount="30"> <h2 style="text-align: center;"><font color="#000099"><b>Find ESMO On Social Media</b> </font></h2><div style="text-align: center;"><a href=https://www.twitter.com/myesmo target="_blank"><img src="/uploads/twnew.png" style="text-align: initial;" width=65 height=65></a><Read more
2024 18 Dec
<marquee behavior="slide" direction="left" scrollamount="30"> <h2 style="text-align: center;"><font color="#000099"><b>Find ESMO On Social Media</b> </font></h2><div style="text-align: center;"><a href=https://www.twitter.com/myesmo target="_blank"><img src="/uploads/twnew.png" style="text-align: initial;" width=65 height=65></a><Read more
2023 22 Aug
According to a new study, a 10-minute MRI scan could be used to screen men for prostate cancer. The scans demonstrated significantly higher accuracy in diagnosing cancer compared to blood tests that rely on finding high levels of a protein known as PSA. MRI technology successfully identified several serious cancers that would have gone undetected...Read more
2023 03 May
A three-year Pan-European project, known as the PRAISE-U project, aims to reduce morbidity and mortality caused by prostate cancer through smart early detection. Prostate cancer is the leading and second leading cause of cancer death among men in northern and western Europe. Every year, an estimated 450,000 European men are diagnosed with prostate...Read more
2022 01 Mar
Innovative rhPSMA Theranostic technology has the potential to offer both diagnostic imaging and treatment for patients affected by prostate cancer. Blue Earth Therapeutics has exclusive worldwide rights to therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) radiopharmaceutical technology. “ We are increasingly...Read more
2021 09 Nov
Prostate cancer is a common disease that can often be quite tricky to deal with. It is a heterogeneous disease, with some patients having a very aggressive form of cancer while others with slower progression of the disease. Management and care of patients with prostate cancer is thus a complex and long-term challenge. Patients require surveillance,...Read more
2021 14 Oct
Siemens Healthineers recently added non-small cell lung cancer support to its AI Pathway Companion. Currently supported pathways are non-small cell lung and prostate cancer. Siemens first presented its AI Pathway Companion at the 2018 Annual Meeting of the Radiological Society of North America in Chicago. In summary, the system delivers artificial...Read more
2021 08 Oct
Executive Summary Cancer care is becoming increasingly complex and personalized. More and more patient characteristics and disease specific data – clinical history, comorbidities, imaging, laboratory data, genomics/ proteomics, lifestyle factors, pathology results – have to be factored in when deciding on diagnostic measures and care pathways....Read more
2021 30 Aug
Late-breaking research from the PRONOUNCE trial was presented in a Hot Line session at ESC Congress 2021. The cardiovascular safety of androgen deprivation therapy (ADT) for prostate cancer remains unresolved after the trial was terminated early. Every year, approximately one million men are diagnosed with prostate cancer worldwide. These patients...Read more
2021 12 Jul
A lone and discordant voice supported by few at first, biparametric prostate magnetic resonance imaging has been gradually gaining attention and visibility as a reliable, faster, and cheaper alternative to conventional multiparametric magnetic resonance imaging and could become a new standard of care in the near future. Key Points The role...Read more
2021 25 Jan
Prostate cancer is one of the most common cancers among men. Patients are determined to have prostate cancer based on Prostate-Specific Antigen (PSA), a prostate-specific antigen used as an index for the screening of prostate cancer. However, diagnostic accuracy for prostate cancer is as low as 30%. That is why a large number of patients have to undergo...Read more
2020 21 Apr
A research predicts a decline in cancer mortality rates in 2020 in the EU. However, due to the COVID-19 pandemic cancer patient safety is compromised, but can still be improved with certain policies. You may also like : Prostate is Now Most Common Cancer Cancer in the EU Total cancer mortality rates in the...Read more
2020 29 Jan
Prostate cancer is now the most commonly diagnosed cancer in England. According to the data revealed by Public Health England (PHE), in 2018 (latest data available), it overtook breast cancer for the first time. You may also like: RSNA 2019: Novel MRI-Guided Ultrasound Treatment Destroys Prostate Cancer This is attributed...Read more
2019 02 Dec
Good news for men with prostate problems including prostate cancer and benign prostate enlargement. A new minimally invasive method, the MRI-guided transurethral ultrasound ablation (TULSA), has been shown to be effective in treating prostate cancer with minimal side effects, according to a new study presented at the annual meeting...Read more
2018 04 Jul
A large number of radiotracers are currently being evaluated for prostate-specific membrane antigen (PSMA) PET, which is becoming a central tool in the staging of prostate cancer, according to a review published in the American Journal of Roentgenology. Staging in various clinical contexts of prostate cancer, such as the preoperative setting...Read more